Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110™, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

Intellia Therapeutics

CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations.

Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?

Vertex Pharmaceuticals

The companies are collaborating on a potential blockbuster.

Better Buy: Vertex Pharmaceuticals vs. CRISPR

CRISPR Therapeutics (CRSP) receives clearance from Health Canada to initiate clinical studies for VCTX210, its investigational therapy for the treatment of type 1 diabetes.

CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug

-Initiation of patient enrollment expected by year-end- -Initiation of patient enrollment expected by year-end-

CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes

CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. The post Being First Is Not Enough For Crispr Therapeutics appeared first on InvestorPlace.

Being First Is Not Enough For Crispr Therapeutics

The gene-editing specialist's stock is now down roughly 37% year to date.

Why CRISPR Therapeutics Stock Fell 18.4% in October

CRISPR Therapeutics (CRSP) reports narrower-than-expected Q3 loss. Yet, revenues miss estimates for the third quarter of 2021.

CRISPR Therapeutics (CRSP) Q3 Earnings Beat, Revenues Lag

Vertex, Inc.

Vertex plans to develop gene-editing therapies with Mammoth Biosciences.

Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics

-Achieved target enrollment in CTX001 clinical trials for beta thalassemia (TDT) and sickle cell disease (SCD); regulatory submissions planned for late 2022-

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

Intercept Pharma

Ligand Pharmaceuticals

Novavax

Vaxart

Based on analysts' loftiest price targets, these drugmakers could double to nearly quintuple investors' money over the next 12 months.

5 Biotech Stocks With 105% to 386% Upside, According to Wall Street

Beam Therapeutics

Teladoc

These stocks are risky, though, and ideally suited for aggressive investors.

3 Stocks Cathie Wood Is Buying That You Might Want to Consider Too

On CRISPR Therapeutics' (CRSP) Q3 earnings call, investor focus will likely be on updates on the company's pipeline candidates, especially its lead candidate CTX001.

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: CRISPR Therapeutics AG (CRSP) Q3 Earnings Expected to Decline

Editas Medicine

Esperion Therapeutics

Marriott

Penn Entertainment

Another day of strong earnings is pushing the broad markets higher across the board.

Tuesday Afternoon Analyst Upgrades and Downgrades: CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and More

Arcturus Therapeutics

These growth stocks could rebound in a big way.

3 Beaten-Down Stocks Cathie Wood Is Buying That Wall Street Thinks Will Skyrocket

Adaptimmune Therapeutics

These two novel-drug makers could be top takeover targets next year.

2 Top Healthcare Stocks That Could Be Bought Out in 2022

CRISPR Therapeutics was down at one point 10% after hours following reports of poorer than expected efficacy levels for its CTX110 CAR-T cell therapy. CRISPR is currently (55%) off all-time highs set at the beginning of 2021.

Crispr Therapeutics: The Future Of Gene Therapy

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Wednesday.

Cathie Wood's ARK Invest Buys Over 675,000 More Shares of CRISPR

Shares of CRISPR Therapeutics AG (NASDAQ: CRSP) fell just under 10% on Wednesday as the biotech firm presented updated data for the phase 1 trial of its blood cancer candidate CTX 110.  RBC Capital maintained a ‘sector perform' rating In a new research report on Wednesday, RBC Capital Markets maintained a “sector perform” rating on […] The post CRISPR price outlook: RBC sees upside to $117 appeared first on Invezz.

CRISPR price outlook: RBC sees upside to $117

Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. The post CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today appeared first on InvestorPlace.

CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today

Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.

Why CRISPR Therapeutics Stock Is Sinking Today

CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-cell malignancies. “We are excited to share positive data from our CARBON trial, which show that CTX110 could offer patients with large B-cell lymphomas an immediately available ‘off-the-shelf' therapy with efficacy similar to autologous CAR-T and a differentiated safety profile,” said Samarth Kulkarni, CEO of CRISPR Therapeutics.

Why CRISPR Therapeutics Stock Is Tumbling Today

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a sell-off drove the stock price down over 50% to its current level of around $100.

Will CRISPR Stock Rebound After A 17% Fall In A Month?

The ARK Innovation ETF and ARK Genomic Revolution ETF cumulatively snapped up hundreds of thousands of shares in Crispr in the past week.

News for CRISPR Therapeutics Stock (CRSP)